Stockreport

Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Protara Therapeutics, Inc.  (TARA) 
PDF Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025Expect to present interim analysis from [Read more]